With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...

A device in clinical development appears to be far safer and more effective than the TAVI devices currently being used ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing ...

The benefits of early TAVR for patients with asymptomatic, severe aortic stenosis are consistent regardless of NT-proBNP or ...

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

JenaValve today announced new results from an expanded cohort receiving its Trilogy transcatheter heart valve (THV) system.

Aortic stenosis is a condition where the aortic valve narrows, obstructing blood flow from the heart to the aorta. As a ...